Formulation and Evaluation of Piroxicam Fast Dissolving Tablets Using Direct Compression and Sublimation Method
Objective: In the present research work, fast dissolving tablets of Piroxicam were formulated by two different techniques i.e. direct compression method and sublimation method using different superdisintegrants.
Methods: Twelve formulations were prepared (PXM1 to PXM12) in which first six formulation were prepared by direct compression technique and other six formulation were prepared by sublimation method by using camphor as a sublimating agent.
Result and Discussion: All the formulations were subjected for precompression, post compression parameters, and shows all the data within the specific limits. Formulation PXM4 containing 5 % crospovidone showed 99.480 ± 0.291 % drug release in 20 min which was more than the drug release of rest of the formulations. The optimized formulation PXM4 was compared with the marketed formulation and it revealed that drug release of PXM4 was found to be 99.397 ± 0.751 % in 20 min, which was greater than the marketed formulation. Finally, results were statistically analysed by the application of one way ANOVA and t-test. The stability study of the optimized formulation PXM4 showed no significant changes in, drug content, disintegration time and in-vitro drug release.
Conclusion: Piroxicam can be successfully prepared using direct compression technique and it will enhance the drug dissolution, which will further increase absorption and bioavailability of the drug.
Keywords: Direct compression, fast dissolving tablets, sublimation, Piroxicam.
2. Heer D, Aggarwal G, Kumar SLH. Recent trends of fast dissolving drug delivery system - an overview of formulation technology. Pharmacophore: An International Research Journal. 2013; 4(1):1-9.
3. Desale KY, Bankar VH, Gaikwad PD, Pawar SP. Review on fast dissolving/disintegrating tablets. Int. J. Pharm. Sci. Review & Res. 2011; 11(1):152-158.
4. Shukla D, Chakraborty S, Singh S, Mishra B. Mouth dissolving tablets: an overview of formulation technology. Sci Pharm. 2009; 76:309-326.
5. Srivastava S, Bala R, Joshi B, Rana AC, Singh V. Mouth dissolving tablets: a future compaction. Int. Res. J. Pharmacy. 2012; 3(8):98-109.
6. Hannan PA, Khan JA, Safiullah S. Oral dispersible system: a new approach in drug delivery system. Indian J. Pharm. Sci. 2016; 78(1):2-7.
7. Lindgren S, Janzon L. Dysphagia: prevalence of swallowing complaints and clinical finding. Med. Clin. North Am. 1993; 77:3-5.
8. Parashar B, Yadav V, Maurya B, Sharma L. Fast dissolving tablet. Int. J. App. Pharm. 2012; 4(2):17-22.
9. Pandey P, Dahiya M. Oral disintegrating tables: a review. Int. J. Pharma Res. & Review. 2016; 5(1):50-62.
10. Mettu SR, Veerareddy PR. Formulation evaluation and pharmacokinetics of flurbiprofen fast dissolving tablet. British. J. Pharm. Res. 2013; 3(4):617-631.
11. Katzung BG. Basic and clinical pharmacology. 10th ed. McGraw companies. U.S.A. 2007, pp. 816.
12. Adeyeye MC, Brittain HG. Preformulation in solid dosage form development. Informa health care. USA. 2008; 178, pp. 1-2.
13. Singh NS, Patil UK. Solubility and preformulation study of non micronized piroxicam SEDSS. Journal of Pharmaceutical Research & clinical Practice. 2014; 4(1):42-52.
14. Ashform M. Assessment of biopharmaceutical properties. In: Aulton ME. Aulton’s pharmaceutics the design and manufacturing of medicines. 3rd ed. Churchill Livingstone, pp. 304-322.
15. Jabbbar ASA, Hussein AA. Formulation of piroxicam liquisolid compacts. Int. J. Pharm. Sci. 2012; 5(1):132-141.
16. Singh S, Shyale SS, Bhosale G. Formulation and evaluation of mouth dissolving tablets of piroxicam. Int. J. Pharm. Sci. Nanotech. 2015; 8(3):2941-2946.
17. Ravi KN, Palanichamy S, M Rajesh T, Godwin Rajadhas, V Anusha, N Parasakthi, Thirupathi AT. Formulation and evaluation of orodispersible piroxicam tablets. J. Pharm. Sci. & Res. 2010; 2(10):615-621.
18. Patil BS, Rao DK, Kulkarni U, RC Hariprasanna, Gada M.M. Formulation and evaluation of fast dissolving tablets of granisetron hydrochloride by direct compression technique. Int. Curr. Pharm. Res. 2011; 3(2):124-128.
19. Modasiya MK, Lala II, Prajapati BG, Patel VM, Shah DA. Design and characterization of fast dissolving tablets of piroxicam. Int. J. PharmTech. Res. 2009; 1(2):353-357.
20. Chaudhari KP, Jadhao UT, Chaudhari CD, Thakare VM, Tekade BW, Chaudhari CS. Formulation and evaluation of fast dissolving sublingual tablets of amlodipine besylate. Der Pharmacia Sinica. 2014; 5(4):1-9.
21. Jalwal MP, Nirja R. Formulation and evaluation of fast dissolving tablet of Domperidone. Int. J. Pharma Professional Res. 2014; 5(3):1067-1074.
22. Kurra N, Baru CR, Vidyadhara KP, Vanitha. Formulation and evaluation of fast dissolving sublingual lisinopril tablets. Indo American Journal of Pharmaceutical Sciences. 2014; 1(6):378-391.
23. Khokhar P, Shukla V. Formulation and evaluation of fast dissolving tablets of diclofenac sodium using PVP. Int. J. Pharma. Res. & Review. 2014; 3(7):12-19.
24. Rajput N, Thakare VM, Tekade BW, Chaudhari KP, Jadhao UT. Formulation and evaluation of fast dissolving tablet by inclusion complexation. Asian Journal of Pharmaceutical Science & Technology. 2014; 4(1):15-20.
25. Padmaja B, Ramakrishna R, Goud G. Formulation and evaluation of fast dissolving tablets of ranitidine hydrochloride. Journal of Pharmacy Research. 2015; 9(2):165-169.
26. Nagar PK, Nayyar P, Sharma PK. Formulation and evaluation of piroxicam fast dissolving tablets using different natural superdisintegrants. Journal of Drug Delivery & Therapeutics. 2014; 4(4):55-59.
27. Iyer S, Sivakumar R, Siva P, Sajeeth CI. Formulation and evaluation of fast dissolving tablets of risperidone solid dispersion. Int. J. Pharmaceutical, Chemical and biological Sciences. 2013; 3(2):388-397.
28. Palanichamy S, Kiran NR, M Rajesh, Jeganath S, Thangathirupathi A. Formulation development and evaluation of piroxicam orodispersible tablets using different superdisintegrant. Des. Pharmacia Lettre. 2011; 3(4):155-162.
29. Nagendra DK, Keshavshetti GG, Pratibha. Design and evaluation of fast dissolving tablets of metoclopramide hydrochloride using synthetic and natural superdisintegrants. Unique Journal of Pharmaceutical and Biological Sciences. 2014; 2(1):16-24.
30. Sudarsanam P, Balakrishanan M, Sireesha VR, Prasad PV. Saitha Kommi. Formulation and evaluation of piroxicam delayed release tablets. Int. J. Pharm.Drug. Anal. 2016; 4(6):318-328.
31. Bhargav E, Reddy CSP, Sowmya C, Haranath C, Khan KAA, K Rajesh et al., Formulation and optimization of piroxicam orodispersible tablets by central composite design. J. Young Pharm. 2017; 9(2):187-191.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).